SEC Filing Summary: Landec Corporation (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Landec Corporation (not Lifecore Biomedical, Inc.) on April 5, 2022. The report discloses the issuance of a press release containing consolidated financial results for the third quarter of fiscal year 2022, which ended on February 27, 2022.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the referenced press release (Exhibit 99.1), which is furnished but not included in the text of this 8-K summary.
Material Changes
The document does not detail specific material changes versus the prior comparable period. It serves solely as a notification that the Q3 2022 results have been announced via a press release.
Guidance, Outlook, and Risks
The filing text contains no management commentary, forward-looking guidance, risk factors, or discussion of unusual items. The report explicitly states that the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and shall not be incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the actual financial figures (revenue, net income, EPS) by reviewing Exhibit 99.1 (Press Release dated April 5, 2022).
- Confirm the discrepancy between the requested company name (Lifecore Biomedical) and the filing registrant (Landec Corporation).
- Review the full press release for any guidance or outlook not captured in this 8-K notification.
- Note that the financial data in this specific 8-K text is not legally "filed" under Section 18 of the Exchange Act.